peripheral t cell lymphoma

Showing 1 - 25 of 53

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

Recruiting
  • Peripheral T Cell Lymphoma
  • +2 more
  • Chidamide combined with Duvillisib
  • Xiamen, Fujian, China
    The First Affiliated Hosptial of Xiamen University
Nov 28, 2023

Venetoclax Tablets Crushed and Dissolved Into a Solution

Not yet recruiting
  • Hematologic Malignancy
  • +18 more
  • 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
Nov 8, 2023

Circulating Tumor DNA Sequencing in Peripheral T-cell Lymphomas

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • circulating tumoral DNA detection
  • Rouen, France
    Centre Henri Becquerel
Oct 13, 2023

Peripheral T Cell Lymphoma Trial in Harlingen (Belinostat Injection, Pralatrexate Injection, CHOP)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Belinostat Injection
  • +3 more
  • Harlingen, Texas
    Valley Cancer Associates
Oct 16, 2023

Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Peripheral T Cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing/China, China
  • +1 more
Oct 9, 2023

Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • CAR-T Therapy
  • Hefei, Anhui, China
  • +7 more
Jul 31, 2023

Peripheral T Cell Lymphoma Trial in Zhengzhou (Golidocitinib, CHOP Regimen)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jul 18, 2023

Peripheral T Cell Lymphoma, Epigenetic Repression Trial in Tianjin (Chidamide, Azacitidine)

Recruiting
  • Peripheral T Cell Lymphoma
  • Epigenetic Repression
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jul 14, 2023

Peripheral T Cell Lymphoma Trial in Shandong, Shanghai, Sichuan (84-gene penal)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • 84-gene penal
  • Shandong, China
  • +2 more
Jul 6, 2023

(CHANT)Real World Study of Duvelisib in Treatment of

Not yet recruiting
  • Follicular Lymphoma
  • +5 more
  • (no location specified)
Jun 20, 2023

Peripheral T Cell Lymphoma Trial in Zhengzhou (SHR0302)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jun 2, 2023

Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

Not yet recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Peripheral T Cell Lymphoma
  • (no location specified)
May 30, 2023

Advanced Cancer, Follicular Lymphoma, Peripheral T Cell Lymphoma Trial (BR1733)

Not yet recruiting
  • Advanced Cancer
  • +3 more
  • (no location specified)
Feb 27, 2023

T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

Not yet recruiting
  • T-Cell Non-Hodgkin Lymphoma
  • +14 more
  • WU-CART-007
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 17, 2023

Peripheral T Cell Lymphoma Trial in Duarte, Aurora, Philadelphia (Nivolumab and EPOCH)

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Nivolumab and EPOCH
  • Duarte, California
  • +2 more
Jan 6, 2023

Minimal Residual Disease in Peripheral T-cell Lymphoma

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Tumor biopsy
  • +2 more
  • Boston, Massachusetts
  • +2 more
Dec 19, 2022

Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma Trial in United States (brentuximab vedotin)

Terminated
  • Hodgkin Lymphoma
  • +2 more
  • brentuximab vedotin
  • Anaheim, California
  • +18 more
Dec 6, 2022

Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)

Recruiting
  • Peripheral T Cell Lymphoma
  • Azacitidine Injection
  • +6 more
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Nov 8, 2022

Peripheral T Cell Lymphoma Trial in Houston (Tenalisib)

Withdrawn
  • Peripheral T Cell Lymphoma
  • Houston, Texas
    The University of Texas MD Anderson Cancer Center
Oct 13, 2022

Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Oct 11, 2022

T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • +4 more
  • anti-CD7 CAR-T cells
  • Shanghai, China
    Xianmin General Song
Aug 29, 2022

Peripheral T Cell Lymphoma Trial in Zhejiang (Mitoxantrone liposome?Chidamide?Azacitidine)

Recruiting
  • Peripheral T Cell Lymphoma
  • Mitoxantrone liposome态Chidamide态Azacitidine
  • Zhejiang, Zhejiang, China
    Second Affiliated Hospital, School of Medicine, Zhejiang Univers
Aug 9, 2022

Peripheral T Cell Lymphoma Trial in France (Chemotherapy + follow up, Chemotherapy + ASCT + follow up)

Recruiting
  • Peripheral T Cell Lymphoma
  • Chemotherapy + follow up
  • Chemotherapy + ASCT + follow up
  • Amiens, France
  • +47 more
Aug 2, 2022

Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

Active, not recruiting
  • Anaplastic Large Cell Lymphoma
  • +4 more
  • Duarte, California
  • +3 more
Jul 21, 2022